Observational studyThe American journal of gastroenterology2017
Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control.
Observational study in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.Gastroenterology · 2024Guideline
- Cryotherapy for persistent Barrett's esophagus after radiofrequency ablation: a systematic review and meta-analysis.Gastrointestinal endoscopy · 2018Pooled it
- Review
- Role of Endoscopy in the Diagnosis and Management of Esophageal Cancer.Journal of clinical medicine · 2025Review
- Applications of cryotherapy in premalignant and malignant esophageal disease: Preventing, treating, palliating disease and enhancing immunogenicity?World journal of gastrointestinal oncology · 2025Review
- Impact of post RFA treatment on neosquamous epithelium microstructure.Scientific reports · 2024Observational
- Improving clinical outcomes of Barrett's esophagus with high dose proton pump inhibitors and cryoablation.Annals of medicine · 2023Article
- Translating Molecular Biology Discoveries to Develop Targeted Cancer Interception in Barrett's Esophagus.International journal of molecular sciences · 2023Review
- Magnetic sphincter augmentation: considerations for use in Barrett's esophagus.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2023Article
- Novel histologic score predicts recurrent intestinal metaplasia after successful endoscopic eradication therapy.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2023Article
- What Is "Cold" and What Is "Hot" in Mucosal Ablation for Barrett's Oesophagus-Related Dysplasia: A Practical Guide.Life (Basel, Switzerland) · 2023Review
- Barrett's Esophagus: An Updated Review.Diagnostics (Basel, Switzerland) · 2023Review
- An Endoscopic and Histologic Study on Healing of Radiofrequency Ablation Wounds in Patients With Barrett's Esophagus.The American journal of gastroenterology · 2022Article
- Today's Mistakes and Tomorrow's Wisdom in Endoscopic Treatment and Follow-Up of Barrett's Esophagus.Visceral medicine · 2022Review
- State-of-the-art management of dysplastic Barrett's esophagus.Gastroenterology report · 2022Review
- Clinical and pathological predictors of failure of endoscopic therapy for Barrett's related high-grade dysplasia and early esophageal adenocarcinoma.Surgical endoscopy · 2021Article
- The Influence of Different Treatment Strategies on the Long-Term Prognosis of T1 Stage Esophageal Cancer Patients.Frontiers in oncology · 2021Article
- Cryoballoon ablation for treatment of patients with refractory esophageal neoplasia after first line endoscopic eradication therapy.Endoscopy international open · 2020Article
- Management of Barrett's esophagus with dysplasia refractory to radiofrequency ablation.World journal of gastroenterology · 2020Review
- Indications, contraindications and limitations of endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma.Therapeutic advances in gastroenterology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRecent data suggest that effective control of gastroesophageal reflux improves outcomes associated with endoscopic eradication therapy (EET) for Barrett's esophagus (BE). However, the impact of reflux control on preventing recurrent intestinal metaplasia and/or dysplasia is unclear. The aims of the study were: (a) to determine the effectiveness and durability of EET under a structured reflux management protocol and (b) to determine the impact of optimizing anti-reflux therapy on achieving complete eradication of intestinal metaplasia (CE-IM).
methodsConsecutive BE patients referred for EET were enrolled and managed with a standardized reflux management protocol including twice-daily PPI therapy during eradication. Primary outcomes were rates of CE-IM and IM or dysplasia recurrence.
resultsOut of 221 patients enrolled (46.0% with high-grade dysplasia/intramucosal carcinoma, 34.0% with low-grade dysplasia, and 20.0% with non-dysplastic BE) an overall CE-IM of 93% was achieved within 11.6±10.2 months. Forty-eight patients did not achieve CE-IM in 3 sessions. After modification of their reflux management, 45 (93.7%) achieved CE-IM in a mean of 1.1 RFA sessions. Recurrence occurred in 13 patients (IM in 10(4.8%), dysplasia in 3 (1.5%)) during a mean follow-up of 44±18.5 months. The only significant predictor of recurrence was the presence of a hiatal hernia. Recurrence of IM was significantly lower than historical controls (10.9 vs. 4.8%, P=0.04).
conclusionsThe current study highlights the importance of reflux control in patients with BE undergoing EET. In this setting, EET has long-term durability with low recurrence rates providing early evidence for extending endoscopic surveillance intervals after EET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.